Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Pre-clinical protective efficacy of novel Chagas vaccine candidates: A final step towards clinical application

Erandeni in labThis project is in collaboration with:

London School of Hygiene and Tropical Medicine: Professor John M. Kelly, Department of Pathogen Molecular Biology, LSHTM

Chagas disease, caused by Trypanosoma cruzi remains a neglected tropical disease in the Americas, affecting approximately 7.5 million people. An efficacious vaccine would be a major, cost-effective approach to improving public health in the Americas.

Two leading Chagas vaccine antigens have been used to develop MVA and adenoviral vectored vaccines at the Jenner Institute. The vaccine candidates induced outstanding immunogenicity in mice and we are joining efforts with Prof. John Kelly’s group, leading various LSHTM scientists to assess protective efficacy using novel transgenic parasites developed in this institution.

Efficacy demonstration will be key for translation to a clinical trial.

This project is supported by MRC-DPFS scheme